Latest News
Lundbeck reports results from long-term follow-up of epilepsy patients treated with bexicaserin
8 December 2025 - Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) on Saturday announced positive results from a long-term follow-up in patients that have been treated with bexicaserin (LP352) for up to two years.Bexicaserin is an invest...
CARsgen Therapeutics presents CT0596 study data at 2005 ASH Annual Meeting
8 December 2025 - CARsgen Therapeutics Holdings Limited (HK:2171), a Chinese developer of innovative CAR T-cell therapies, said on Sunday that it has presented clinical data from a study of its allogeneic BCMA-targeted CAR T-cell product candidate, C...
AsymBio starts commercial production at Shanghai Fengxian Manufacturing Base
8 December 2025 - AsymBio, a China-based global Contract Development and Manufacturing Organisation (CDMO) and a subsidiary of Asymchem Group (SZ:002821, HK:6821), announced on Monday that it has commenced commercial production at its Shanghai Fengxi...
Natera acquires Foresight Diagnostics to expand MRD capabilities
5 December 2025 - Cell-free DNA testing company Natera Inc (NASDAQ:NTRA) announced on Friday that it has acquired Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection for cancer.The all-stock transaction includ...
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
5 December 2025 - Dermatology specialist Galderma (SWX:GALD) announced on Friday that its regenerative biostimulator Sculptra has received EU Medical Device Regulation (MDR) certification, extending its use beyond facial applications to the gluteal a...